Please ensure Javascript is enabled for purposes of website accessibility

Why Pacific Biosciences of California Inc Is Down Big Today

By Brian Feroldi - Jan 11, 2016 at 2:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A slower than hoped for launch of the company's new Sequel System is pressuring shares on Monday.

What: Shares of Pacific Biosciences of California (PACB 10.71%), a company focused on DNA sequencing, were down more than 15% as of 1:15 p.m. EST after the company provided investors with a an update related to the launch of its new DNA sequencing system.

So what: Pacific Biosciences of California announced that it has received 49 orders for its new Sequel System since they became available for sale in October. Ten of those 49 orders have already been shipped to customers and a total of six of those systems were installed during the fourth quarter. The company plans to install the remaining four systems later this month.

PacBio stated that these new systems were shipped with an early software and chemistry version and it has plans to provide updates for both during the first quarter.

While those results look encouraging, the reason for the sell-off appears to be related to a sourcing issue for the company's new SMRT Cells that work in the Sequel Systems. The cells are currently being sourced from one of the company's prototype chip vendors and they are expected to be in a limited supply through the first half of year. PacBio plans to restrict the pace of new Sequel Systems shipments during the first half of the year until it can secure an increase in its supply SMRT Cells. The company is currently working to increase the supply of the new SMRT Cells to a high-volume manufacture and anticipates the issue should be resolved by mid-year.

Now what: While the slower than hoped for ramp in system shipments is bummer news, I think these results provide reasons to be optimistic. PacBio said that more than 40% of its 49 systems orders came from new customer sites, which is a good sign that the company's new system is competing well with Illumina's (ILMN -8.40%) offerings. That's important, as PacBio has longed been overshadowed by Illumina as its previous system -- the RS II -- was too expensive to effectively grab market share. However, its new Sequel System is smaller, cheaper, and more capable than its previous models so, which will allow it to better compete with Illumina.

Michael Hunkapiller, the CEO of Pacific Biosciences, will be providing investors with more details about its launch Tuesday during a presentation at the JP Morgan Healthcare Conference.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool recommends Illumina and Pacific Biosciences of California. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pacific Biosciences of California, Inc. Stock Quote
Pacific Biosciences of California, Inc.
PACB
$8.79 (10.71%) $0.85
Illumina, Inc. Stock Quote
Illumina, Inc.
ILMN
$208.32 (-8.40%) $-19.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.